Table 3.
Recommendations for treating to target in Crohn’s disease by the International Organization for the Study of Inflammatory Bowel Diseases[19]
| Crohn’s disease | Ulcerative colitis |
| The consensus target is a combination of: | |
| Clinical/1PRO remission defined as resolution of abdominal pain and diarrhea or altered bowel habits which should be assessed every 3 mo until resolution then 6-12 mo thereafter. and Endoscopic remission2 defined as resolution of ulceration at ileocolonoscopy which should be assessed at 6-9 mo intervals during the active phase | Clinical/1PRO remission defined as resolution of rectal bleeding and diarrhea or altered bowel habits which should be assessed every 3 mo until resolution then 6-12 mo thereafter. and Endoscopic remission2 defined as resolution of friability and ulceration at flexible sigmoidoscopy or colonoscopy3 which should be assessed at 3 mo intervals during the active phase |
| Adjunctive measures of disease activity that may be useful in the management of selected patients but are not a treatment target include: | |
| •Faecal calprotectin | •CRP •Faecal calprotectin •Histology |
| Measures of disease activity that are not a target: | |
| •Histology •Cross-sectional imaging | •Cross-sectional imaging |
1
Patient reported outcomes;
2
When endoscopy cannot adequately evaluate inflammation, resolution of inflammation as assessed by cross-sectional imaging can be substituted;
3
While Mayo subscore of 0 may be defined as the target, there is currently insufficient evidence to recommend it in all patients; only Mayo subscore of 0-1 can be systematically recommended in practice.